Connecting Hydroxychloroquine in Vitro Antiviral Activity to in Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients with Coronavirus Disease 2019

Clinical Infectious Diseases

Volumn 71, Issue 12, 2020, Pages 3232-3236

  Fan, Jianghong ^a   Zhang, Xinyuan ^a   Liu, Jiang ^a   Yang, Yuching ^a   Zheng, Nan ^a   Liu, Qi ^a   Bergman, Kimberly ^a   Reynolds, Kellie ^a   Huang, Shiew Mei ^a   Zhu, Hao ^a   Wang, Yaning ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

antiviral activity; COVID 19; hydroxychloroquine; SARS CoV 2

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CHLOROQUINE; HYDROXYCHLOROQUINE; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; EC50; ENDOSOME; GOLGI COMPLEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MAXIMUM CONCENTRATION; PARTITION COEFFICIENT; PREDICTION; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TROUGH CONCENTRATION;

ANTIVIRAL AGENTS; COVID-19; HUMANS; HYDROXYCHLOROQUINE; SARS-COV-2;

EID: 85087162639     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa623     Document Type: Article

References (22)

1. Ya o X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71:732-9.
2. Fu D, Zhou J, Zhu WS, et al. Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem 2014; 6:614-22.
3. Zhang X, Zheng N, Zou P, Zhu H, Hinestroza J P, Rosania GR. Cells on pores: a simulation-driven analysis of transcellular small molecule transport. Mol Pharm 2010; 7:456-67.
4. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2:69.
5. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloro-quine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6:16.
6. MacIntyre AC, Cutler DJ. Kinetics of chloroquine uptake into isolated rat hepato-cytes. J Pharm Sci 1993; 82:592-600.
7. US Food and Drug Administration. Aralen: chloroquine phosphate. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/006002s043lbl.pdf. Accessed 26 May 2020.
8. Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am 2003; 17:599-613.
9. Bergqvist Y, Domeij-Nyberg B. Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr 1983; 272:137-48.
10. Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmaco-kinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988; 26:303-13.
11. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989; 27:771-9.
12. Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother 2009; 53:1468-75.
13. Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, Rajasingham R, Young JH, Nicol MR. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness [manuscript published online ahead of print 28 April 2020]. Clin Pharmacol Ther 2020. doi:10.1002/cpt.1874
14. Garcia-Cremades M, Solans B P, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing [manuscript published online ahead of print 14 April 2020]. Clin Pharmacol Ther 2020. doi:10.1002/cpt.1856
15. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 57:279-83.
16. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020; 14:241-6.
17. Arnold SL, Buckner F. Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection [manuscript published online ahead of print 8 April 2020]. Clin Transl Sci 2020. doi:10.1111/cts.12797
18. Kapoor KM, Kapoor A. Role of chloroquine and hydroxychloroquine in the treatment of COVID-19 infection-a systematic literature review. medRxiv [Preprint]. Posted 30 March 2020. Available at: doi:https://doi. org/10.1101/2020.03.24.20042366
19. Tansan S. A possible role for single dose hydroxychloroquine for prevention of lethal coronavirus infection. Özel Tansan Polikliniǧi 2020. Available at: https://tansan.com.tr/a-possible-role-for-single-dose-hydroxychloroquine-for-prevention-of-lethal-coronavirus-infection/. Accessed 26 May 2020.
20. Guastalegname M, Vallone A. Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment?. Clin Infect Dis 2020; 71:888-9.
21. Vicente J, Zusterzeel R, Johannesen L, et al. Assessment of multi-ion channel block in a phase I randomized study design: results of the CiPA phase I ECG bio-marker validation study. Clin Pharmacol Ther 2019; 105:943-53.
22. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv [Preprint]. Posted 3 April 2020. Available at: doi:https://doi.org/10.1101/2020.04.02.20047050